NGFR-transduced Autologous T Lymphocytes

NGFR-transduced Autologous T Lymphocytes is a form of adoptive cell therapy that uses genetically modified T cells to target cancer cells. This therapy involves extracting a patient's own T cells, genetically modifying them to express the Nerve Growth Factor Receptor (NGFR), and then reinfusing them back into the patient after lymphodepletion. ## Mechanism and Function NGFR-transduced Autologous T Lymphocytes are engineered to express a truncated version of NGFR that is incapable of eliciting intracellular signaling[6]. This modification serves primarily as a marker for tracking the T cells after infusion rather than as a functional targeting mechanism[6]. The NGFR component allows researchers to monitor the trafficking and persistence of these modified T cells in the body using flow cytometry and other detection methods[1][5]. These modified T cells are typically administered following a lymphodepleting chemotherapy regimen consisting of cyclophosphamide and fludarabine[6][9]. This preparatory regimen creates space for the infused cells, reduces competition for homeostatic cytokines like IL-7 and IL-15, and temporarily depletes immunosuppressive cells that might interfere with the therapy's effectiveness[7]. ## Clinical Applications NGFR-transduced T cells have been investigated primarily in melanoma clinical trials. In one notable study (NCT01740557), these cells were used alongside CXCR2-transduced T cells to improve T cell trafficking to tumors[6]. The NGFR component served as a control for T cell trafficking since human T cells do not naturally express NGFR[6]. The therapy is administered after lymphodepletion and is often supported by high-dose interleukin-2 (IL-2) to facilitate engraftment and function of the infused cells[9]. Patients typically undergo biopsies before lymphodepletion and at day 21 post-infusion to assess chemokine levels and quantify the presence of the transduced T cells[6]. ## Development Status This therapy represents an innovative approach in cancer immunotherapy, with clinical trials focusing primarily on melanoma patients. It belongs to the broader category of adoptive cell therapies, which have shown promising results in treating various cancers, particularly in patients who have progressed through previous treatments[7].